Patient Journey Maps & Patient Co-Creation

STUDY OVERVIEW
BENCHMARK CLASS
STUDY SNAPSHOT
KEY FINDINGS
VIEW TOC AND LIST OF EXHIBITS

As patients are taking an active role in their healthcare decision-making process, pharma organizations are taking rapid steps to become more patient-centric. Among the many patient-centric solutions and strategies, patient journey mapping and patient co-creation are important ways for pharma to listen to the patient voice and gain critical insights.

Forward-looking companies resort to patient journey mapping to tap into a patient’s experience through a disease, from the onset of symptoms to diagnosis, treatment, and management. This understanding is further augmented by establishing co-creation and involving patients early at each stage – whether it is at R&D stage for the creation of lay summaries, developing a new drug or treatment, or co-developing education and support resources.

Best Practices, LLC undertook this benchmarking research to help biopharma leaders improve patient-centric growth by probing innovative approaches, successful practices, and recommended vendors which are delivering high impact across patient journey mapping and patient co-creation. This report delivers insights around patient journey mapping capabilities, structure, staffing, high-impact areas, sources, validation, updates, automation, vendors, innovation and KPIs – and overall leadership support of patient-centric initiatives. It also establishes benchmarks around patient co-creation programs, key design phases, engagement channels, high-impact areas, and innovative trends.

Video Brief:

Industries Profiled:
Biopharmaceutical; Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Clinical Research; Laboratories

Companies Profiled:
Alkermes; Astellas; AstraZeneca; Bayer; BELLUS Health; Biogen; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; CSL Behring; Debiopharm; Eli Lilly and Company; GlaxoSmithKline ; Janssen; Jazz Pharmaceuticals; Kala Pharmaceuticals; Inc.; Mitsubishi Tanabe Pharma Corporation; Novartis; Novo Nordisk; Organon; OTSUKA; Pfizer; Sanofi; Sunovion; Takeda Pharmaceuticals; UCB Pharma

Study Snapshot

Best Practices, LLC engaged representatives from 26 biopharma manufacturers in this benchmark research study. To enhance the quality of research insights, nine qualitative interviews were conducted with high-performing benchmark participants.

Key topics covered in this report include:

Patient Journey Mapping Capabilities, Structure, and Staffing
Patient Journey Mapping Sources, Impact, and Validation
Patient Journey Mapping Tools, Updates, and Automation
KPIs to Measure Patient Journey Mapping Capability
Vendors for Innovative Patient Journey Approaches
Use of Patient Co-creation Programs
Effective Channels for Co-creation
Frequency of Co-Creation Insights Utilization

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

Pull Through of Patient Journey Maps: Effective pull through of patient journey maps is driven by top-down support and patient measurement component for all teams.

Value Fronts for Patient Co-Creation: Top-rated value fronts for co-creation include #1 Improving digital health tools (wearables, adherence, biomonitoring, apps), #2 Identify pain points, and #3 Improving customer experience design.

Table of Contents

Sr. No.	Topic	Slide No.
I.	Executive Summary	Pg. 3-19
II.	Maximizing Patient Journey Map Capabilities	Pg. 20-48
III.	Maximizing Patient Co-Creation	Pg. 49-64
IV.	APPENDIX A: Study Participants & Data Summary	Pg. 65-73
V.	APPENDIX B: Additional Voices from the Field	Pg. 74-79
VI.	About Best Practices, LLC	Pg. 80

List of Charts & Exhibits

I. Executive Summary

Key insight on patient centricity
Key insight on pull through of patient journey maps
Key insight on staffing dedicated to patient journey maps
Key insight on maximizing patient journey mapping capability with dedicated patient insights group
Key insight on clinical support
Key insight on building patient journey maps
Key insight on KPIs for assessing PJM capabilities
Key insight on using innovative patient segmentation
Key insight on patient co-creation impact
Key insight on co-creation usage
Key insight on external partnerships

II. Maximizing Patient Journey Map Capabilities

Hallmarks of patient centricity
Interview narrative on the reasons for having a patient centric organization
Interview narrative around steering committees
Teams and resources used by benchmark organizations to support each facet of the overall patient journey mapping capability
Teams and resources used by benchmark organizations to build journey maps and to provide insights
Teams and resources used by benchmark organizations to take actions on maps and to manage pull through of maps
Interview narrative around internal storytelling
Interview narrative around internal teams
Approximate number of employees working on building patient journey maps across the entire organization
Approximate number of employees working on building patient journey maps across the entire organization – High patient-centricity vs. Mid patient-centricity vs. Low patient-centricity segment
Top sources for building patient journey maps
Steps taken by benchmark organizations to validate the patient journeys built
Level of impact of patient journey maps in strategic planning
Interview narrative around patient journey mapping insights
Interview narrative around how journey maps can aid patient-driven trial design
Level of impact of patient journey maps in tactical customer engagement
Interview narrative around an integrated customer experience improvement system
Level of impact of patient journey maps in innovation
Reasons why benchmark organizations update a patient journey map
Interview narrative around improvements to patient journey maps
Automated journey mapping tools or platforms used at benchmark organizations to update patient journey maps
KPIs used by benchmark organizations to measure the success of their patient journey mapping capability
Percentage of companies using KPIs to measure patient journey mapping capability; Average number of KPIs used to measure patient journey mapping capability – High patient-centricity vs. Mid patient-centricity vs. Low patient-centricity segment
Interview narrative around measuring patient journey mapping capability
Interview narrative around return on investment on patient journey maps
Interview narrative around groups who make an impact
Recommended patient journey mapping tools
Vendors recommended for innovative patient journey approaches

III. Maximizing Patient Co-Creation

Use of patient co-creation in the development of new initiatives
Interview narrative on co-creation and patient insights
Interview narrative around communicating patient voice
Commitment to patient co-creation
Interview narrative around clinical trials
Co-creation management
Interview narrative around sourcing co-creation
Effective channels for directly interacting and collaborating with patients to co-create new solutions
Utilization of co-creation insights for strategic planning
Utilization of co-creation insights for tactical customer engagement
Utilization of co-creation insights for innovation
Co-creation success stories
Frequency of co-creation insights utilization for strategic or tactical decisions
Frequency of co-creation insights utilization for strategic or tactical decisions – High patient-centricity vs. Mid patient-centricity vs. Low patient-centricity segment
Interview narrative around evaluating new programs

IV. APPENDIX A: Study Participants & Data Summary

Research overview: Objectives, methodology and participants
Participant job titles
Therapeutic areas represented in the study
Key benchmark findings: Hallmarks of patient centricity; Patient journey mapping capability; Staffing; and Patient journey mapping sources
Key benchmark findings: Validation and Pull through impact
Key benchmark findings: KPIs and Updates, automation & tools
Key benchmark findings: Use of patient co-creation; Co-creation management; and Collaboration channels
Key benchmark findings: Patient co-creation utilization and Frequency of use

V. APPENDIX B: Additional Voices from the Field

Interview narrative around increasing the accuracy of patient journey maps
Interview narrative around integrating patient voice into modern clinical trial design
Interview narrative around map building and utilization
Interview narrative around drawing medical society insights
Interview narrative around utilizing the right data sources and groups to build the patient journey

Patient-Driven Growth: Maximizing Patient Journey Maps & Patient Co-Creation

ID: POP-362

Features:

Pages: 80

Published: 2023

Delivery Format: Shipped

Video Brief:

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63F1CE1E6D578BB84002589720027B676
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/patient-driven-growth-maximizing-patient-journey-maps-co-creation
18
19
20172.69.6.77
21
22
23527255.sherryhk.tech
24/bestp/domrep.nsf
25BMR